A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Small Cell Lung Cancer(ALTER1202)

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Small Cell Lung Cancer(ALTER1202)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2017

At a glance

  • Drugs Anlotinib (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ALTER1202
  • Sponsors Chia Tai Tianqing Pharmaceutical Group
  • Most Recent Events

    • 06 Mar 2017 Status changed from not yet recruiting to recruiting.
    • 01 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top